VF
HBIO icon

Virtu Financial’s Harvard Bioscience HBIO Stock Holding History

Virtu Financial’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,951
Closed -$40K – 1910
2025
Q4 		$40K Buy
+5,951
New +$35.3K ﹤0.01% 1329
2025
Q3 		– Sell
-2,654
Closed -$12K – 1721
2025
Q2 		$12K Buy
+2,654
New +$11.1K ﹤0.01% 1304
2024
Q3 		– Sell
-3,539
Closed -$101K – 1569
2024
Q2 		$101K Buy
+3,539
New +$124K 0.01% 827
2023
Q3 		– Sell
-2,001
Closed -$110K – 1537
2023
Q2 		$110K Buy
+2,001
New +$110K 0.01% 1016
2022
Q4 		– Sell
-1,792
Closed -$46K – 1834
2022
Q3 		$46K Buy
+1,792
New +$59.3K ﹤0.01% 1221
2019
Q3 		– Sell
-4,329
Closed -$87K – 1574
2019
Q2 		$87K Buy
+4,329
New +$127K 0.01% 1152

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $118M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $315M AUM 58.44% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial's HBIO Position: Q1 2026 in Review

Virtu Financial sold out of Harvard Bioscience (HBIO) in Q1 2026, closing a stake of 5,951 shares — an estimated $40K sold.

Virtu Financial first reported a position in HBIO in Q2 2019 and held it in 6 quarters. The position peaked at $110K in Q2 2023. 37 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

  • Virtu Financial reported no remaining Harvard Bioscience position as of Q1 2026 after selling out during the quarter.
  • Virtu Financial sold 5,951 Harvard Bioscience shares in Q1 2026, an estimated $40K.
  • Virtu Financial first reported a position in Harvard Bioscience in Q2 2019 and held it in 6 quarters.
  • Virtu Financial's Harvard Bioscience position peaked at $110K in Q2 2023.
  • 37 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.